2.43
0.07 (2.75%)
| Penutupan Terdahulu | 2.37 |
| Buka | 2.36 |
| Jumlah Dagangan | 1,568,765 |
| Purata Dagangan (3B) | 2,497,546 |
| Modal Pasaran | 237,213,344 |
| Harga / Jualan (P/S) | 4.39 |
| Harga / Buku (P/B) | 17.38 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Nov 2025 |
| Margin Operasi (TTM) | -758.05% |
| EPS Cair (TTM) | -3.04 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 310.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 49.88% |
| Nisbah Semasa (MRQ) | 3.08 |
| Aliran Tunai Operasi (OCF TTM) | -208.21 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -103.52 M |
| Pulangan Atas Aset (ROA TTM) | -36.80% |
| Pulangan Atas Ekuiti (ROE TTM) | -140.82% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Editas Medicine, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.38 |
|
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.33% |
| % Dimiliki oleh Institusi | 57.56% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |